Therapeutics for Inflammatory Diseases: Current Challenges and Future Market

Table of Contents

• INTRODUCTION
  • STUDY GOAL AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • STUDY SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS CREDENTIALS
  • RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTSBY TYPE OF DISEASES, THROUGH 2010 ($ MILLIONS)
  • Summary Figure: ESTIMATED GLOBAL MARKET SHARE FOR ANTI-INFLAMMATORY TREATMENTS BY SELECTED DISEASES, 2005 AND 2010 (%)
• OVERVIEW
  • THE IMMUNE SYSTEM AND THE INFLAMMATORY RESPONSE
    • NONSPECIFIC IMMUNITY
    • SPECIFIC IMMUNITY
  • CELL-MEDIATED IMMUNITY
  • HUMORAL IMMUNITY
  • THE ROLE OF MEDIATORS IN THE INFLAMMATORY RESPONSE
  • Table 1 MEDIATORS OF INFLAMMATION AND THEIR FUNCTION(S)
    • COMPLEMENT
      • Complement Inhibitors in Development
  • Table 2 COMPLEMENT INHIBITORS IN DEVELOPMENT
    • Cytokines
      • Functions of Cytokines
    • Anti-Inflammatory Cytokines
  • Table 3 CYTOKINES WITH ANTI-INFLAMMATORY ACTIVITY
  • Table 4 SOLUBLE CYTOKINE RECEPTORS WITH ANTI-INFLAMMATORY ACTIVITY
    • Two Categories of Cytokines Involved in Inflammation
  • Table 5 CATEGORIES OF CYTOKINES
    • BIOLOGICAL RESPONSE MODIFIERS
  • Table 6 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
  • Table 7 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
  • Table 7 (CONTINUED)
  • Table 7 (CONTINUED)
  • Table 8 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
  • Table 8 (CONTINUED)
  • Table 8 (CONTINUED)
  • Table 9 TUMOR NECROSIS FACTORS (TNFS), THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Biological Response Modifiers Important to the Inflammatory Process
    • Chemokines
    • Interleukins
      • Interleukin-2
      • Other Infection-Fighting Cells
      • Side Effects
    • Tumor Necrosis Factor (TNF)
    • MAJOR ANTI-INFLAMMATORY CYTOKINES WITH THERAPEUTIC INDICATIONS
  • Table 10 ANTI-INFLAMMATORY CYTOKINES IN CLINICAL DEVELOPMENT
    • IL-1RA
    • IL-4
    • IL-6
    • IL-10
    • IL-11
    • IL-13
    • TGF-ß
    • SUPPRESSORS OF CYTOKINE SIGNALING
  • Table 11 SUPPRESSORS OF CYTOKINE SIGNALING AND THEIR POTENTIAL THERAPEUTIC AREAS
    • CURRENT PRODUCT CATEGORIES FOR INFLAMMATORY DISEASES
      • ANTIBODY-BASED PRODUCTS
  • Table 12 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ANTI-INFLAMMATORY DISEASES
    • Antibodies in Development for the Treatment of Inflammatory Diseases
  • Table 13 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
  • Table 13 (CONTINUED)
  • Table 13 (CONTINUED)
  • Table 13 (CONTINUED)
  • Table 13 (CONTINUED)
  • Table 13 (CONTINUED)
  • Table 13 (CONTINUED)
    • DRUGS IN DEVELOPMENT FOR INFLAMMATORY DISEASES
  • Table 14 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
  • Table 14 (CONTINUED)
    • TARGETS FOR ANTI-INFLAMMATORY DRUGS
      • NUCLEAR FACTOR KB
      • TOLL-LIKE RECEPTORS
        • Toll-Like Receptors (Continued)
• APPLICATIONS AND PRODUCTS
  • CATEGORIES OF PRESCRIPTION ANTI-INFLAMMATORY PRODUCTS ON THE WORLD MARKET
    • CORTICOSTEROIDS
    • DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
    • IMMUNOMODULATORS
  • THE MARKET FOR ANTI-INFLAMMATORY DRUGS BY CATEGORY
  • Table 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 1 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, 2003-2010 ($ MILLIONS)
    • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON THE MARKET
  • Table 16 CURRENTLY MARKETED NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
  • Table 16 (CONTINUED)
    • COX-2 INHIBITORS
      • The Market for COX-2 Inhibitors
  • Table 17 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
  • Figure 2 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
  • Table 18 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
  • Figure 3 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
    • Next-Generation Cox-2 Inhibitors
    • BIOLOGICAL RESPONSE MODIFIERS
      • Il-1 Inhibitors
      • Tumor Necrosis Factor Inhibitors
    • INDICATIONS
      • Ankylosing Spondylitis
        • Anti-Inflammatory Drugs Approved for the Treatment of Ankylosing Spondylitis
        • The Market for Drugs to Treat Ankylosing Spondylitis
  • Table 19 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR ANKYLOSING SPONDYLITIS, THROUGH 2010 ($ MILLIONS)
    • Anti-inflammatory Drugs in Development for the Treatment of Ankylosing Spondylitis
    • Humira
    • Asthma
      • Asthma (Continued)
    • Chronic Obstructive Pulmonary Disease (COPD)
      • The Role of Cytokines in Asthma
      • Currently Marketed Products
  • Table 20 ASTHMA DRUG CATEGORIES AND SELECTED PRODUCTS
  • Table 20 (CONTINUED)
  • Table 21 SELECTED BRANDED ANTI-INFLAMMATORY AND BRONCHODILATING DRUGS USED TO TREAT ASTHMA
  • Table 21 (CONTINUED)
    • Anti-Inflammatory Drugs Used to Treat Asthma
      • Corticosteroids
      • Leukotriene Modifiers
      • IgE Inhibitors
      • Phosphodiesterase Inhibitors
      • Mast-Cell Inhibitors
    • Efficacy of Available Drugs
    • Top-Selling and Recently Introduced Anti-Inflammatory Products to Treat Asthma and COPD
      • Advair/Seretide
      • Alvesco
      • Azmacort
      • Singulair
      • Xolair
    • The Market for Anti-Inflammatory Drugs to Treat Asthma
  • Table 22 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 4 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
  • Table 23 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 5 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, 2003-2010 ($ MILLIONS)
  • Table 24 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 6 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
    • The Market for Anti-Inflammatory Drugs to Treat COPD
  • Table 25 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 7 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
  • Table 26 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
  • Figure 8 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
  • Figure 9 ESTIMATED GLOBAL MARKET SHARE FOR ANTI-INFLAMMATORY DRUGS TO TREAT ASTHMA/COPD, BY CATEGORY, 2005 AND 2010 (%)
    • Anti-Inflammatory Products in Development for the Treatment of Asthma and COPD
      • Adhesion Molecule Antagonists
      • Cytokine Antagonists
      • IgE Antagonists
      • Oligonucleotide and Gene Therapies
      • Phosphodiesterase Inhibitors
      • Phosphodiesterase �E(Continued)
  • Table 27 PHOSPHODIESTERASE INHIBITORS IN PHASE II OR LATE DEVELOPMENT
    • Transcription-factor Antagonists
    • Tumor Necrosis Factor-Alpha Inhibitors
    • 1018 ISS
    • 159797
    • 678007
    • 685698
    • 766994
    • 799943
    • Advair/Seretide and Serevent
    • AVE 0675/AVE 7279
    • AWD12-281
    • CAT-354
    • CC-10004
    • Daclizumab/R35
    • Daxas
    • EPI-12323
    • IC485
    • Mepolizumab
    • NVA237
    • ONO-6126
    • Pleconaril
    • QAB149
    • R411
    • Xolair
    • Technology Approaches to the Development of New Anti-Inflammatory Drugs to Treat Asthma
  • Table 28 TARGETS AND APPROACHES TO THE DEVELOPMENT OF ANTI- INFLAMMATORY DRUGS TO TREAT ASTHMA
    • Inflammatory Bowel Diseases
      • Crohns Disease
      • Irritable Bowel Syndrome
      • Ulcerative Colitis
      • Products Used to Treat Inflammatory Bowel Diseases
        • Remicade
      • Other Recently Introduced Products
      • The Market for Drugs to Treat Inflammatory Bowel Disease
  • Table 29 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 10 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, 2003-2010 ($ MILLIONS)
    • Anti-Inflammatory Products in Development for the Treatment of Inflammatory Bowel Diseases
      • 270384
      • 683699
      • Alequel
      • Alicaforsen
      • Apaza
      • BMS-561392
      • Cilansetron
      • ISIS-104838
      • Kappaproet
      • LDP-02
      • Leukine
      • Onercept
      • RDP58
      • Renzapride
      • STA-5326
      • Talnetant
      • Teduglutide
    • Antibody Products in Development for the Treatment of Inflammatory Bowel Diseases
      • ABT-874
      • Cimzia
      • CNTO 1275
      • Humicade
      • Humira
      • HuZAF
      • Leukine
      • MLN02
      • Nuvion
      • Remicade
      • Tysabri
    • Biological Response Modifiers in Development of the Treatment of Crohns Disease
  • Table 30 BIOLOGICAL RESPONSE MODIFIERS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CROHNS DISEASE
    • Multiple Sclerosis
      • Marketed Anti-Inflammatory Products for the Treatment of Multiple Sclerosis
        • Cytokine-Based Products
        • Avonex
        • Betaseron
        • Rebif
        • Tysabri (formerly Antegren)
        • Tysabri �EContinued)
      • The Market for Anti-Inflammatory Drugs to Treat Multiple Sclerosis
  • Table 31 GLOBAL MARKET FOR ANTICYTOKINE ANTI- INFLAMMATORY TREATMENTS FOR MULTIPLE SCLEROSIS, THROUGH 2010 ($ MILLIONS)
    • Anti-Inflammatory Drugs in Development for the Treatment of Multiple Sclerosis
    • Antibody-Based Products
    • Other Products in Development
    • Psoriasis
      • Recently Introduced Anti-Inflammatory Treatments for Psoriasis
        • Enbrel
        • Raptiva
        • Remicade
      • Other Approved Biologic Products for the Treatment of Psoriasis
        • Amevive
      • Other Anti-Inflammatory Drugs for the Treatment Of Psoriasis
        • 6-Thioguanine
        • Accutane
        • Hydrea
        • Isa247
        • Mycophenolate Mofetil
        • Ontak
        • Sulfasalazine
      • Phototherapy in the Treatment of Psoriasis
      • The Market for Anti-Inflammatory Drugs to Treat Psoriasis
  • Table 32 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 11 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
    • Products in Development for the Treatment of Psoriasis
    • Antibody Products in Development for the Treatment of Psoriasis
    • Antibody Products (Continued)
    • Other Anti-Inflammatory Products in Development for the Treatment of Psoriasis
    • Photodynamic Therapy (PDT) for the Treatment of Psoriasis
      • The FDA Approves PDT
      • Early Problems with PDT
      • Technology Breakthroughs in The 1980s
      • Improved Photosensitizing Agents
      • New Light Sources
      • The Two Stages of PDT Treatment
      • Choosing the Correct Wavelength
      • The Role of Singlet Oxygen
      • Dual Control Mechanisms of PDT
      • Mechanisms of PDT-Induced Cell Death
      • Direct Cell Kill
      • Indirect Cell Kill via Vascular Damage
      • Immunological Response of PDT
      • Applications
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
      • Currently Available Treatments
  • Table 33 COMMONLY USED DMARDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    • Currently Available �E(Continued)
  • Table 34 CURRENTLY AVAILABLE BIOLOGIC PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    • Antibody-Based Products
    • Enbrel
      • Humira/Trudexa
      • Remicade
    • Other Biological Products
      • Kineret
      • Tumor Necrosis Factor Inhibitors
    • Cost of Biological Agents to Treat Rheumatoid Arthritis
    • Market Possibilities for Biologic Treatments
  • Figure 12 CATEGORIES OF DRUGS USED IN CONJUNCTION WITH TNF-ALPHA INHIBITORS (%)
    • The Market For TNF-Alpha Inhibitors
  • Table 35 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, THROUGH 2010 ($ MILLIONS)
  • Figure 13 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, 2003-2010 ($ MILLIONS)
    • Other Products Used to Treat Arthritis
      • Cox-2 Inhibitors
      • Celebrex
      • Mobic
    • The Market for Anti-Inflammatory Drugs to Treat Rheumatoid Arthritis
  • Table 36 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
  • Figure 14 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, 2003-2010 ($ MILLIONS)
  • Table 37 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2010 ($ MILLIONS)
  • Figure 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, 2003-2010 ($ MILLIONS)
  • Figure 16 ESTIMATED GLOBAL PRESCRIPTION MARKET SHARE FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS, BY CATEGORY, 2005 (%)
    • Products in Development to Treat Rheumatoid Arthritis
      • Antimetabolites
      • Chemotaxis Inhibitors
      • Complement Inhibitors
      • Cytokine Inhibitors
    • Other DMARDs in Development
    • Antibody-Based Products
  • Table 38 PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
  • Table 38 (CONTINUED)
  • Table 38 (CONTINUED)
    • ACZ885
    • AMG 108
    • AMG 162
    • AMG 714
    • Anti-CD20 (Second Generation)
    • Arcoxia
    • BMS-561392
    • Cimzia
    • CNTO 148
    • Eculizumab
    • Humax-CD4
    • Humax-CD20
    • Humira
    • Il-1 Trap
    • IL-18 Binding Protein
    • ISIS-104838
    • Lymphostat-B
    • MLN1202
    • Orencia
    • PEGsTNF-RI
    • PMI-005
    • Prexige
    • Pro70769
    • R1569
    • Remicade
    • Rituxan/Mabthera
    • SCIO-323
    • SCIO-469
    • Tenovil
• INDUSTRY
  • THE VIOXX FALLOUT
    • THE VIOXX FALLOUT (CONTINUED)
    • THE VIOXX FALLOUT (CONTINUED)
    • CREATING AN UNWARRANTED MARKET?
    • THE FDA TAKES A HARD LOOK AT DIRECT-TO-CONSUMER (DTC) ADVERTISING
    • FUTURE OF COX-2 INHIBITORS
      • Future of COX-2 Inhibitors (Continued)
    • THE EFFECT OF INSURANCE COMPANY REIMBURSEMENT
• COMPANY PROFILES
  • ABBOTT LABORATORIES
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
    • CORPORATE STRATEGY
  • ALEXION PHARMACEUTICALS, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCT CANDIDATES
    • COMPANY STRATEGY
  • ALTANA PHARMA AG
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
    • CORPORATE STRATEGY
  • AMGEN, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
  • Table 39 AMGENS ANTI-INFLAMMATORY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • BIOGEN IDEC, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 40 BIOGEN IDECS ANTI-INFLAMMATORY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
      • BUSINESS OVERVIEW
      • PRODUCTS
  • Table 41 CAMBRIDGE ANTIBODY TECHNOLOGYS ANTI-INFLAMMATORY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • CELGENE CORPORATION
      • BUSINESS OVERVIEW
      • PRODUCTS
      • FINANCIAL INFORMATION
      • CORPORATE STRATEGY
    • DYNAVAX TECHNOLOGIES CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS IN DEVELOPMENT
      • CORPORATE STRATEGY
    • EPIGENESIS PHARMACEUTICALS
      • BUSINESS OVERVIEW
      • PRODUCTS IN DEVELOPMENT
      • CORPORATE STRATEGY
    • GENENTECH, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • GENMAB A/S
      • BUSINESS OVERVIEW
      • PRODUCTS
      • CORPORATE STRATEGY
    • GLAXOSMITHKLINE PLC
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 42 GLAXOSMITHKLINES ANTI-INFLAMMATORY PRODUCT PIPELINE
  • Table 42 (CONTINUED)
    • CORPORATE STRATEGY
    • ISIS PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • MILLENNIUM PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 43 MILLENNIUMS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • NOVARTIS AG
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • PROTEIN DESIGN LABS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 44 PROTEIN DESIGN LABS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • REGENERON PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCT CANDIDATES
      • CORPORATE STRATEGY
    • SCHERING-PLOUGH CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY

  LIST OF TABLES

• Summary Table:
• Table 1 MEDIATORS OF INFLAMMATION AND THEIR FUNCTION(S)
• Table 2 COMPLEMENT INHIBITORS IN DEVELOPMENT
• Table 3 CYTOKINES WITH ANTI-INFLAMMATORY ACTIVITY
• Table 4 SOLUBLE CYTOKINE RECEPTORS WITH ANTI-INFLAMMATORY ACTIVITY
• Table 5 CATEGORIES OF CYTOKINES
• Table 6 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
• Table 7 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
• Table 8 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
• Table 9 TUMOR NECROSIS FACTORS (TNFS), THEIR NATURAL SOURCES AND MAJOR EFFECTS
• Table 10 ANTI-INFLAMMATORY CYTOKINES IN CLINICAL DEVELOPMENT
• Table 11 SUPPRESSORS OF CYTOKINE SIGNALING AND THEIR POTENTIAL THERAPEUTIC AREAS
• Table 12 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ANTI-INFLAMMATORY DISEASES
• Table 13 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
• Table 14 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
• Table 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 16 CURRENTLY MARKETED NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
• Table 17 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
• Table 18 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
• Table 19 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR ANKYLOSING SPONDYLITIS, THROUGH 2010 ($ MILLIONS)
• Table 20 ASTHMA DRUG CATEGORIES AND SELECTED PRODUCTS
• Table 21 SELECTED BRANDED ANTI-INFLAMMATORY AND BRONCHODILATING DRUGS USED TO TREAT ASTHMA
• Table 22 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 23 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 24 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 25 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 26 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
• Table 27 PHOSPHODIESTERASE INHIBITORS IN PHASE II OR LATE DEVELOPMENT
• Table 28 TARGETS AND APPROACHES TO THE DEVELOPMENT OF ANTI- INFLAMMATORY DRUGS TO TREAT ASTHMA
• Table 29 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 30 BIOLOGICAL RESPONSE MODIFIERS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CROHNS DISEASE
• Table 31 GLOBAL MARKET FOR ANTICYTOKINE ANTI- INFLAMMATORY TREATMENTS FOR MULTIPLE SCLEROSIS, THROUGH 2010 ($ MILLIONS)
• Table 32 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 33 COMMONLY USED DMARDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
• Table 34 CURRENTLY AVAILABLE BIOLOGIC PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
• Table 35 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, THROUGH 2010 ($ MILLIONS)
• Table 36 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Table 37 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2010 ($ MILLIONS)
• Table 38 PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
• Table 39 AMGENS ANTI-INFLAMMATORY PRODUCT PIPELINE
• Table 40 BIOGEN IDECS ANTI-INFLAMMATORY PRODUCT PIPELINE
• Table 41 CAMBRIDGE ANTIBODY TECHNOLOGYS ANTI-INFLAMMATORY PRODUCT PIPELINE
• Table 42 GLAXOSMITHKLINES ANTI-INFLAMMATORY PRODUCT PIPELINE
• Table 43 MILLENNIUMS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 44 PROTEIN DESIGN LABS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE

  LIST OF FIGURES

• Summary Figure:
• Figure 1 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 2 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
• Figure 3 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
• Figure 4 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 5 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 6 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 7 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 8 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 9 ESTIMATED GLOBAL MARKET SHARE FOR ANTI-INFLAMMATORY DRUGS TO TREAT ASTHMA/COPD, BY CATEGORY, 2005 AND 2010 (%)
• Figure 10 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 11 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
• Figure 12 CATEGORIES OF DRUGS USED IN CONJUNCTION WITH TNF-ALPHA INHIBITORS (%)
• Figure 13 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, 2003-2010 ($ MILLIONS)
• Figure 14 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, 2003-2010 ($ MILLIONS)
• Figure 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, 2003-2010 ($ MILLIONS)
• Figure 16 ESTIMATED GLOBAL PRESCRIPTION MARKET SHARE FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS, BY CATEGORY, 2005 (%)